Abstract:ImportanceNeoadjuvant chemotherapy (NAC) is a standard treatment option for locally advanced gastric cancer (LAGC); however, the indications for adjuvant chemotherapy (AC) in patients with LAGC who received NAC remain controversial.ObjectiveTo compare survival rates between patients with LAGC who received AC and those who did not after NAC followed by surgery.Design, Setting, and ParticipantsThis multicenter, international cohort study included 353 patients with LAGC undergoing curative-intent gastrectomy after NAC at 2 tertiary referral teaching hospitals in China between June 1, 2008, and December 31, 2017. To externally validate the findings in the Chinese patients, 109 patients from the US and Italy between June 1, 2006, and June 30, 2013, were reviewed. The follow-up period of the Chinese patients was completed in December 2020, and the follow-up period of the Western patients was completed between February and July 2017. Data analysis was performed from December 1, 2020, to February 28, 2021.ExposuresPatients who received AC and those who did not were propensity score matched to evaluate the association of AC with survival.Main Outcomes and MeasuresOverall survival (OS), disease-free survival, and disease-specific survival.ResultsOf 353 patients from China (275 [78.1%] male; mean [SD] age, 58.0 [10.7] years), 262 (74.1%) received AC and 91 (25.9%) did not. After propensity score matching, the 3-year OS was significantly higher in patients who received AC (60.1%; 95% CI, 53.1%-68.1%) than in those who did not (49.3%; 95% CI, 39.8%-61.0%) (P = .02). Lymph node ratio (LNR) was significantly associated with AC benefit (P < .001 for interaction), and a plot of the interaction between LNR and AC demonstrated that AC was associated with improved OS in patients with higher (≥9%) LNRs (3-year OS: 46.6% vs 21.7%;P < .001), but not in patients with LNRs less than 9% (3-year OS: 73.9% vs 71.3%;P = .30). When stratified by AC cycles, only those patients who completed at least 4 AC cycles exhibited a significant survival benefit in the 6-month (hazard ratio, 0.56; 95% CI, 0.33-0.96;P = .03) and 9-month landmark analysis (hazard ratio, 0.50; 95% CI, 0.27-0.94;P = .03). In the external cohort, improved OS with AC administration was also found in patients with LNRs of 9% or greater (3-year OS: 53.0% vs 26.3%;P = .04).Conclusions and RelevanceIn this cohort study, the administration of AC after NAC and resection of LAGC was associated with improved prognosis in patients with LNRs of 9% or greater. These findings suggest that LNR might be valuable in AC selection in future decision-making processes.

Optimizing treatment sequence for inoperable locally advanced breast cancer: Long‐term outcomes of surgery first versus neoadjuvant chemotherapy in a real‐world setting

Can Laparoscopic Nerve-Sparing Ultra-Radical Hysterectomy Play a Role in Locally Advanced Cervical Cancer? A Single-Center Retrospective Study

Neoadjuvant Chemotherapy with Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: the Randomized, Phase III OPTICAL Trial

Surgery paradigm for locally advanced breast cancer following neoadjuvant systemic therapy

Neoadjuvant chemotherapy vs upfront resection: A challenging choice in resectable pancreatic ductal adenocarcinoma.

Neoadjuvant Chemotherapy Improves Overall Survival in Resectable Colorectal Liver Metastases Patients with High Clinical Risk Scores-- A Retrospective, Propensity Score Matching Analysis.

Locoregional recurrence and survival of breast−conserving surgery compared to mastectomy following neoadjuvant chemotherapy in operable breast cancer

Surgical Options of the Breast and Clinical Outcomes of Breast Cancer Patients after Neoadjuvant Chemotherapy: A Single-Center Retrospective Study

The Impact of Neoadjuvant versus Adjuvant Chemotherapy on Survival Outcomes in Locally Advanced Breast Cancer

Upfront Surgery As First-Line Therapy in Selected Patients with Stage IIIA Non–small Cell Lung Cancer

Impact of response to neoadjuvant chemotherapy on surgical modality in patients with T1-2N0-1M0 triple-negative breast cancer

Impact of Preoperative vs Postoperative Radiotherapy on Overall Survival of Locally Advanced Breast Cancer Patients

Comparison of breast-conserving surgery with mastectomy in locally advanced breast cancer after good response to neoadjuvant chemotherapy

Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy

Outcome of Patients with Locally Advanced Rectal Cancer Pursuing Non-Surgical Strategy in National Cancer Database

Preoperative chemotherapy in upfront resectable colorectal liver metastases: New elements for an old dilemma?

Upfront surgery for stage IIIA/B non-small cell lung cancer: retrospective cohort study

Oncological outcomes of neoadjuvant chemotherapy in patients with resectable synchronous colorectal liver metastasis: A result from a propensity score matching study

Clinical Impact of Delaying Surgery in Patients Undergoing Neoadjuvant Chemotherapy on Breast Cancer Recurrence and Survival

Neoadjuvant Chemotherapy Versus Surgery As the Initial Option for T3 Breast Cancer (>5 Cm): Real-World Evidence from the Chinese Society of Clinical Oncology Breast Cancer Database

Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral resection